As China's population ages and medical costs continue to rise, pressure on social health insurance funds is intensifying. At the same time, demand for high-cost, cutting-edge treatments-such as cell and gene therapies-is growing rapidly.
Please login to read the full news
Note that your comment may be edited or removed in the future, and that your comment may appear alongside the original article on websites other than this one.
more »